Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. reports company developments as a medical device company focused on epilepsy care through the RNS System, a brain-responsive neuromodulation platform that monitors brain electrical activity and delivers personalized electrical stimulation at the seizure source. Recurring updates cover RNS System revenue, financial results, gross margin, research and development spending, and corporate outlook commentary.
NeuroPace news also includes clinical evidence for drug-resistant focal epilepsy and broader epilepsy programs, including post-approval study publications and NAUTILUS trial presentations. Additional announcements include healthcare conference presentations, investor communications, product-platform development, AI-enabled tools, and other clinical or regulatory disclosures tied to responsive neurostimulation.
NeuroPace, Inc. (Nasdaq: NPCE) will report its Q1 2021 financial results on June 3, 2021, before market open. A conference call will be held at 5:00 a.m. PT (8:00 a.m. ET) to discuss the results, with investors able to join by dialing (844) 955-2173 for domestic calls or (914) 987-7949 for international calls, using ID: 1485513. NeuroPace specializes in a brain-responsive neuromodulation platform aimed at treating epilepsy, offering a personalized approach to managing debilitating seizures.
NeuroPace, Inc. (Nasdaq: NPCE) successfully completed its initial public offering (IPO) on April 26, 2021, by closing the sale of 6,900,000 shares at $17.00 each. This offering included the full exercise of underwriters' options for 900,000 additional shares, resulting in gross proceeds of approximately $117.3 million. The company focuses on innovative products for epilepsy treatment, with its RNS System being the first brain-responsive platform available. The stock began trading on April 22, 2021.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, announced its initial public offering (IPO) of 6,000,000 shares at $17.00 each, totaling $102 million in gross proceeds. The IPO is expected to close on April 26, 2021. NeuroPace has also granted underwriters an option to purchase an additional 900,000 shares. Trading on Nasdaq is set to begin on April 22, 2021. J.P. Morgan and Morgan Stanley lead the offering, with registration statements already filed with the SEC.